Two likely mechanisms for the initiation of arterial platelet thrombus formation under conditions of elevated fluid shear stresses are: (1) excessive adhesion and aggregation of platelets from rapidly flowing blood onto the exposed subendothelium of injured, atherosclerotic arteries; or (2) direct, fluid shear stress-induced aggregation of platelets in constricted arteries with intact endothelial cells. Mechanism
Two likely mechanisms for the initiation of arterial platelet thrombus formation under conditions of elevated fluid shear stresses are: (1) excessive adhesion and aggregation of platelets from rapidly flowing blood onto the exposed subendothelium of injured, atherosclerotic arteries; or (2) direct, fluid shear stress-induced aggregation of platelets in constricted arteries with intact endothelial cells. Mechanism (1) was simulated using a parallel plate flow chamber, fibrillar collagen type I-coated slides, and mepacrine-labeled (fluorescent) platelets in whole blood anticoagulated with citrate, hirudin, unfractionated porcine heparin, or low molecular weight heparin flowing for l to 2 minutes at wall shear rates of 100 to 3,000 seconds-' (4 to 120 dynes/ cm'). The precise sequence of interactions among von Willebrand factor (vWF), glycoprotein (GP)lb, and GPllb-llla during platelet adhesion and subsequent aggregation were resolved by direct real-time observation using a computerized epifluorescence video microscopy system. Adhesion at high shear rates was the result of the adsorption of large vWF multimers onto collagen and the binding of platelet GPlb to the insolubilized vWF. Aggregation occurred subsequently and required the binding of ligands, including vWF N SMALL ARTERIES partially obstructed by atheroscle-I rosis or vasospasm, fluid shear stresses may increase many-fold above the normal time-average level of about 20 dynes/cm* and may lead to platelet thrombosis. Among the most likely possibilities for the acute initiation of arterial platelet thrombi are: ( 1) excessive adhesion of blood platelets onto the exposed subendothelium of injured arteries and arterioles containing collagen and von Willebrand factor (vWF), with subsequent platelet aggregation and accumulation; or ( 2 ) direct, excessive aggregation of platelets from the blood in constricted areas of the arterial circulation that are lined with intact endothelial cells. Presently, there is controversy regarding the precise sequence of involvement of GPIb and GPIIb-IIIa in platelet adhesion and aggregation onto reactive surfaces. In this report we describe the use of video microscopy coupled with digital imaging techniques to resolve the sequence of platelet adhesion and aggregation events in realtime on fibrillar collagen type I, the collagen type that predominates in atherosclerotic arterial subendothelium.' Using this model of thrombotic mechanism I (simulated by the perfusion of blood over collagen type I at different shear rates*), as well as a model of thrombosis mechanism I1 (simulated by shear stress*-induced platelet aggregation in a rotational cone and plate viscometer), we have investigated the * "Shear" refers to the relative parallel motion between adjacent fluid planes during flow. The difference in the velocity between adjacent layers of blood at various distances from the vessel wall determines the local shear rate, expressed in cm/sec per cm, or inverse seconds (s-I). Fluid shear stress in dynes/cm2 is a measure of the force required to produce a certain rate of flow of a viscous liquid, and is proportional to the product of shear rate and blood viscosity. Fluid shear stresses in the circulation are imposed on the surfaces of blood cells, where they may produce alterations in the structure, exposure or clustering of membrane-associated molecules.
via its RGD binding domain, to GPllb-llla. Mechanism (2) was modeled by producing shear stresses of 90 to 180 dynes/cm' in a rotational cone and plate viscometer, which aggregates platelets from platelet-rich-plasma (PRP) anticoagulated with citrate, hirudin, or either type of heparin in reactions that require large vWF multimers, Caz+, adenosine diphosphate, and both GPlb and GPllb-Ma. Both vWFmediated shear-aggregation in PRP and platelet-collagen adhesion in flowing whole blood (anticoagulated with citrate and hirudin) are inhibited by two potentially useful anti-arterial thrombotic agents: polymeric aurin tricarboxylic acid (ATA; 28.5 to 1 14 pg/mL). which binds to vWF and inhibits its attachment of GPlb, and a recombinant vWF fragment (~VWF"''~-'~~; 30 to 200 pg/mL) that binds to platelet GPlb (in the absence of any modulator) and blocks attachment of vWF multimers. Unfractionated heparin, but not low molecular weight heparin, apparently binds to rvWF"5'733 and counteracts the inhibitory effects of the vWF fragment in vitro on shear-aggregation and platelet-collagen adhesion. 0 1993 by The American Society of Hematology.
effects of new potentially useful anti-arterial thrombotic agents.
It has previously been demonstrated that vWF becomes rapidly insolubilized onto the exposed subendothelium of human arteries,2 as well as onto collagenous components of the vessel wall,324 and that this precedes and augments platelet adhesion.' It has also been shown6 that platelet adhesion to human arterial subendothelium can be inhibited by a monoclonal antibody (MoAb) against glycoprotein (GP)Ib, whereas an MoAb against GPIIb-IIIa eliminates platelet aggregate formation. At higher wall shear rates, the GPIIbIIIa antibody also suppressed the spreading of adherent platelets. Fressinaud et a1' used MoAbs against vWF that prevent its binding to
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GPIb, GPIIb-IIIa, or collagen, and found that all three antibodies inhibited platelet adhesion to equine or human collagen type I11 by -30% at 2,600 s-'; however, a mixture of all three was required to inhibit almost completely platelet accumulation on c~l l a g e n .~~~ In a later report," they also concluded that Arg-Gly-Asp-Ser (RGDStcontaining peptides that block vWF binding to platelet GPIIb-IIIa inhibit vWFmediated platelet adhesion to collagen over 5-minute periods ofblood flow at 2600 s-'. Recently, Sheppeck et all' reported that platelet adhesion to a polyethylene surface at 300 s-' required GPIIb-IIIa, and that GPIb was necessary for subsequent platelet aggregation.
In experiments using purified human I2'I-vWF multimers insolubilized onto glass capillary tubes, Olson et all2 found that the adherence of '"In-labeled platelets (suspended with red blood cells [RBCs] ) to the insolubilized vWF increased progressively as shear rates increased to 2,500 s-'. Both platelet GPIb and GPIIb-IIIa receptors were involved in platelet adhesion onto the glass surfaces coated with the vWF alone.
The various studies cited above used morphometric or radioactive techniques to evaluate the accumulation of platelets on the exposed surfaces after the occurrence of adhesion/ aggregation. In contrast, we have combined a parallel-plate perfusion chamber with a recently developed computerized epifluorescence video microscopy system to observe and quantify the adhesion of human platelets flowing from whole blood onto type I fibrillar collagen, and the subsequent aggregation, as these separate events occurred (ie, in "realtime"). vWF/GPIb interactions were studied specifically by using a monoclonal F(ab'), anti-GPIb antibody known to inhibit vWF binding. Attachment of vWF to GPIIb-IIIa was evaluated using MoAbs against either GPIIb-IIIa or the RGD sequence in vWF that is an essential part of the GPIIb-IIIa binding site of the molecule. Fibrillar collagen type I, the predominate type in atherosclerotic vessels,' was exposed to flowing blood as a model for subendothelial exposure in atherosclerotic arteries following injury and endothelial cell desquamation.
A rotational cone and plate viscometer in which plateletsurface interactions are minimall3 was our model for studying arterial thrombosis mechanism 11. Platelets aggregate from platelet-rich plasma (PRP) or whole blood under conditions of abnormally elevated fluid shear stress in the presence of large or unusually large vWF multimers, adenosine diphosphate (ADP), and Cazf. These components may either be in the fluid exogenous to the or, alternatively, derived from the platelets themselves.15 Shear-induced, vWFmediated platelet aggregation requires both platelet GPIb and GPIIb-IIIa receptor^,'"'^ and does not require ristocetin, other exogenous agents, or chemical modification of vWF. Any possible role of GPIX or GPV, which form a noncovalent complex with GPIb in the platelet membrane,'* in shear effects (including shear-induced signal transduction) has not yet been evaluated.
We studied the effects of polymeric aurin tricarboxylic acid (ATA) and a recombinant fragment of vWF (~v W F~~' -'~~) that contains amino acids 445 to 733 (including binding domains for platelet GPIb, unfractionated heparin, and ~ollagen'~) of the mature vWF monomer in both the viscometer and perfusion models of arterial thrombosis. Polymeric ATA binds to large vWF multimers and prevents their interaction with platelet GPIb under conditions of elevated levels of fluid shear stress,2o22' whereas N W F~~~-~~~ (after reduction and alkylation to prevent polymerization) binds to GPIb in the absence of any m~d u l a t o r . '~ Both ATA and rvWp5-733 inhibit platelet aggregation in vivo in dog2' and monkey2' Folts models of constrictive coronary thrombosis, and it was our additional goal to determine their effects in our two model systems in the presence of citrate, hirudin, unfractionated porcine heparin, and low molecular weight heparin.
MATERIALS AND METHODS
Blood Collection and Preparation
The final concentration of anticoagulant used was either 0.38% wt/vol sodium citrate, 0.3 to IO U/mL (1.8 to 59 pg/mL) unfractionated porcine heparin (heparin sodium; Elkins-Sinn Inc, Cherry Hill, NJ), 1 U/mL (15 pg/mL, anticoagulant activity = 63 U/mg) low molecular weight heparin (Enoxaparin; Rhone Polenc Rorer, King of Prussia, PA), or 200 U/mL recombinant hirudin, a specific thrombin inhibitor (Dr P.H. Johnson, SRI International, Menlo Park, CA). No observable fibrin formation occurred using the various anticoagulants (and combinations) in these concentrations. Blood was collected from nonsmoking and medication-free donors into polypropylene syringes containing anticoagulant with or without 10 pmol/ L of the fluorescent dye mepacrine (quinacrine dihydrochloride; Sigma, St Louis, MO). Mepacrine is concentrated in the dense granules of platelets and the granules of leukocytes and has no effect on normal platelet function at this c~ncentration.'~ These two cell types are clearly distinguished by epifluorescence microscopy. Any fluorescence from within the erythrocytes is quenched by hemoglobin. Leukocytes do not adhere to the collagen-coated surface at the relatively high shear rates used in our studies. Platelet secretion of mepacrine from dense granules after adhesion is sufficiently limited in rate and extent that platelet fluorescence does not decrease detectably under our experimental conditions during adhesion and subsequent aggregation.
Viscometer Experiments
PRP was prepared by centrifugation of citrated, hirudin-treated, or heparinized whole blood at 150g for 15 minutes. After the PRP samples (0.6 mL) were incubated for 5 minutes with either buffer or test sample (MoAb, I V , W F~~' -'~~, or polymeric ATA), two IO-pL aliquots were dispensed into 10 mL of Coulter Isoton I1 (Coulter Electronics, Inc, Hialeah, FL) containing 0.5% glutaraldehyde for a preshear platelet count. The PRP was subjected to controlled shear stress levels ranging from 90 to 180 dynes/cm2 in a stainless steel cone and plate viscometer (Model 781; Ferranti Electric, Inc, Commack, NY) for 30 seconds at room temperature. After shearing, 1 0-pL duplicates of each sample were dispensed into 10 mL of the Isoton/glutaraldehyde. Platelet counts and size distributions were determined with an electronic particle counter (Coulter Multisizer, Coulter Electronics, Inc) using 100-pL sample volumes and a 50-pm diameter aperture. The percent decrease in platelets, compared with unsheared controls, was directly related to the percent of platelet aggregation in each sample."16 Each experiment was repeated at least three times (in duplicate), and the study used more than 20 different normal blood donors.
Preparation of Collagen Solution and Collagen-Coated Coverslips
Suspensions of 2.1 mg/mL type I acid-insoluble collagen fibrils from bovine achilles tendon (Sigma) in 0.5 mol/L acetic acid, pH 
MoAbs
The F(ab')2 portion of MoAb LJ-PI9 was prepared as described previously?6 (The entire U -P 19 causes extensive platelet aggregation, in contrast to the F(ab')z portion.) This antibody reacts with the 45-Kd amino terminus of platelet GPIb, containing the vWF-binding domain and inhibits ristocetin-induced vWF binding to platelets without affecting thrombin-induced vWF binding to GPIIMIIa. 27 The other whole MoAbs used in this study caused no detectable platelet aggregation under our experimental conditions. U-CP8 is a murine monoclonal IgG, that reacts with platelet GPIIb-IIIa and completely blocks the binding of vWF, fibrinogen, vitronectin, and fibr0nectin.2~'~~ U-152B/6 is a murine monoclonal IgG, obtained by immunization with the Arg-Gly-Asp (RGD) sequence and flanking amino acid residues of vWF and reacts specifically with the GPIIbIIIa binding site of vWF, but has no cross-reactivity with the RGDcontaining domains of fibrinogen, fibronectin, or vitronectin.'' U-155B/16 is a murine monoclonal IgG, that binds to the Aa chain of fibrinogen, but not to vWF.~' It does not alter the function of fibrinogen and was used as control, along with vWF fragment buffer (5% [wt/vol] mannitol, 10 mmol/L citric acid, 1.0 mmol/L lysine monohydrochloride, 1.5 mmol/L NaCl, pH 3.5) or HEPES buffer (10 mmol/L HEPES, 145 mmol/L NaC1, 5 mmol/L KCl, 0.5 mmol/L Na2HP04, 1 mmol/L MgS04, pH 7.4). All IgG antibodies were purified on protein-A Sepharose (Sigma)," dialyzed against HEPES buffer, and stored at -40°C until use.
Polymeric ATA
The trisodium salt of ATA (Aldrich Chemical, Milwaukee, WI) was dissolved in phosphate-buffered saline (PBS) (10 mmol/L Na2HP04, 140 mmol/L NaCl, pH 7.4). ATA interacts with vWF and inhibits the binding of large vWF multimers to platelet GPIb. It inhibits ristocetin-induced, vWF-mediated platelet agglutination, and shear-induced, vWF-mediated platelet aggregation in the viscometer in the absence of ristocetin?' Higher molecular weight ATA polymers were separated from lower molecular weight forms at 4°C by a 50-Kd cut-off dialysis membrane (Spectra/Por; Spectrum Medical Industries, Inc, Los Angeles, CA). A filter-sterilized stock solution of 8.5 mg/mL polymeric ATA with a mass greater than 2.5 Kd was prepared and stored at room temperature.
Recombinant v WF Frugment
A cDNA for vWF was cloned from a human cDNA library and a fragment of this cDNA was modified to allow its expression in Escherichia coli, as previously described." rvWF445-733 is composed of amino acid residues 445 to 733 of the mature vWF subunit with the seven cysteine residues reduced and alk~1ated.l~ As originally demonstrated with proteolytic fragments derived from native vWF, synthetic peptides, and MoAbs, rvWF445-733 contains three functional domains of vWF that interact with GPIb, heparin, and ~o l l a g e n .~~-~* Unlike native vWF, rvWF445-733 binds to GPIb without the requirement for exogenous modulators. In the presence of ristocetin or botrocetin, rvWF445-733 inhibits the binding of vWF multimers to GPIb and platelet aggregation." The lyophilized rvWF445-733 was dissolved in distilled water to a stock solution of 12.2 mg/mL. This was aliquoted and stored at -40°C.
Flow Chamber and Perfusion Studies
Before the flow chamber experiments, blood was incubated at 37°C for 15 minutes, and then an additional 5 minutes with either buffer or test sample. Control runs at the beginning and end of each experiment demonstrated a similar extent of platelet accumulation on collagen-coated slides. One side of a parallel-plate flow chamber, described in detail elsewhere," was formed by a collagen-coated glass coverslip with a flow path height of 205 pm (determined by a silicon gasket). The flow chamber was assembled and filled with isotonic saline. A syringe pump (Model 935; Harvard Apparatus, South Natick, MA) was used to aspirate blood through the flow chamber, displacing the saline, at a constant flow rate for 1 to 2 minutes. Flow rates of 0.53,4.24,8.0, and 16.0 mL/min produced 100,800, 1,500, and 3,000 s-' wall shear rates, respectively.'"'These include the relevant range of shear rates in veins and in partially constricted arteries:' and correspond to wall shear stresses of approximately 4,32,60, and 120 dynes/cm2, respectively. Blood was considered a Newtonian fluid with a constant viscosity of 4 cp4' in laminar flow. The entire system was maintained at 37°C by a thermostatic air bath (Model 279; Laboratory Products, Boston, MA). The flow chamber was mounted on an inverted-stage microscope (DIAPHOT-TMD; Nikon, Garden City, NY) equipped with an epifluorescent illumination attachment (TMD-E F Nikon), a 60X FLUOR objective, a 5X projection lens (Nikon), and a silicon-intensified target (SIT) video camera (Model CIOOO; Hamamatsu, Waltham, MA) suitable for very low light levels. Epifluorescence illumination was used to visualize directly platelet adhesion, and subsequent platelet aggregation and accumulation, throughout the perfusion period. The experiments were recorded in real time on a 0.5-in video cassette recorder (JVC model BR-3100U).
Measurement of Platelet Accumulation
The number of platelets deposited at the end of the perfusion period was calculated by scanning the slide and continuously recording the locally averaged fluorescence intensity over the entire field of view, using a motorized microscope stage and a computerized microphotometric measurement system. This system consists of a 40X FLUOR objective and 1 X projection lens (Nikon), a photodiode (Model PIN-IODP/SB United Detector Technology, Hawthorne, CA) connected to the microscope, an amplifier with variable transimpedance gain (Model 101C; United Detector Technology) that also converts the signal from current to voltage, a 12-bit analog to digital converter board (ACSE-I 2; Strawbemy Tree Computers, Inc, Sunnyvale, CA), and a microcomputer (Macintosh SE, Cupertino, CA). More detailed description of the equipment and its capabilities has been published e l s e~h e r e .~~,~~.~~ After direct observation of platelet adhesion and subsequent aggregation in real-time, the collagen-coated slide was dipped in a hemolysing solution (ZAP-OGLOBIN 11 in Coulter Isoton 11) to lyse any RBCs sticking to the surface, and crushed into I mL of 1% Triton X-100 (Rohm and Haas, Philadelphia, PA) to lyse the deposited platelets. The sample was sonicated for 5 seconds and centrifuged at 2408 for 10 minutes to remove glass fragments. The supernatant was assayed for lactate dehydrogenase (LD-14 PL Kit; Gilford Systems, Oberlin, OH) and compared with lysates of known platelet concentrations to determine the total number of platelets on each slide. By integrating the intensity distribution along the collagencoated surface, as recorded by the microphotometric measurement system, an intensity/platelet ratio was determined. The ratio was used to convert fluorescence intensity to platelet density, in millions/cm2, at any axial position from the glass-collagen interface to the end of the collagen-coated ~u r f a c e .~~. '~.~~ By integrating the curve of platelet
For personal use only. on October 3, 2017. by guest www.bloodjournal.org From density versus distance along the length of the slide, the total number of platelets that accumulated up to any point could be calculated. We used the first I O mm from the glass-collagen interface to compute the platelet deposition. The average platelet deposition in millions/ cm2 was obtained by dividing the number of platelets deposited along this IO-mm length by the surface area.
Evaluation of Platelet Adhesion and Subsequent Platelet Aggregation
Videotape images, focused 0.38 mm downstream from the glasscollagen interface, were digitized and computer analyzed after 2 seconds of flow and at 15-second intervals up to 1 minute" (IC-300 Modular Image Processing Workstation; Inovision Corp, Durham, NC). The number of platelet thrombi per 3.7 X IO4 pm2 in the microscope field were determined, along with the number of platelets in each individual thrombus. Three-dimensional representations of the platelet thrombi present at 2, 15, 30,45, and 60 seconds during the perfusion period were constructed and photographed from the computer screen. Platelet adhesion was expressed as the number of individual thrombi/3.7 X IO4 pm2 by using background-subtracted digitized images. The platelet aggregation that occurred subsequent to platelet adhesion was expressed as the number of platelets per thrombus and was equal to the total intensity of each thrombus (area X average intensity) multiplied by a value determined by dividing the number of single platelets in the 2-second images by the sum of the total intensities of these single platelets.
Studies of Severe von Willebrand Disease (v WO) Patient Plasma and Platelets
Perfusion experiments were performed with blood anticoagulated with citrate or porcine heparin from a severe vWD patient whose plasma contains vWF antigen levels that have been less than 1.5 U/ dL on 12 different occasions by immunoradiometric and enzymelinked immunosorbent assays (ELISAs), and vWF multimeric patterns that have been either undetectable or barely visible on prolonged exposure by sodium dodecyl sulfate (SDS)-electrophoresis/autoradiography using patient plasma or platelet^?^ The effect of exogenous vWF on the adhesion of vWD platelets onto collagen was examined by the addition of a final concentration of 100 U/dL (100%) of large vWF multimers to vWD blood samples before perfusion. vWF multimers, consisting predominately of the largest plasma-type forms, were purified from normal human cryoprecipitate using glycine-and NaC1-precipitation followed by 4% agarose gel exclusion chromatography. 15 The multimeric patterns were analyzed by SDS-I% agarose gel electrophoresis followed by overlay with polyclonal 1251-anti-human vWF IgG and autoradiography. In some experiments, PG12-treated vWD and normal platelets were washed in HEPES buffer, as previously described,15 and reconstituted as either vWD platelets resuspended in normal platelet-poor plasma (PPP) or normal platelets in vWD PPP at 400,000 platelets/pL. Normal RBCs were added to produce a 40% hematocrit.
Statistical Analysis
Mean k SEM was calculated for experiments based on three or more determinations. Statistical significance of differences between means was determined for two entries (one control and one test manipulation) by two-tailed paired Student's t-test, and for more than two entries (one control and multiple test manipulations) by repeated measures analysis of variance (single factor factorial-one repeated measure ANOVA)?6,47 In the latter case, if means were shown to be significantly different, multiple comparisons by pairs of each test manipulation with the control were performed by the two-tailed Dunnett's f -t e~t ?~,~~ Probability values less than .05 were considered significant, and less than .01 highly significant.
RESULTS
Shear-Aggregation Experiments
The interaction of large vWF multimers with both platelet GPIb and the GPIIb-IIIa complex is required for the shear-induced aggregation of platelets from normal PRP in a vis~ometer.l~-'~ Experiments were performed to establish the concentrations of MoAbs to be tested subsequently in the perfusion studies. Shear-induced, vWFmediated aggregation in citrated PRP was minimal in the presence of 50 or 100 pg/mL of the anti-GPIb F(ab), , or 100 or 200 pg/mL of the anti-GPIIb-IIIa (data not shown). Shearaggregation was inhibited in a dose-dependent manner by 12.5 to 200 pg/mL ofthe antibody against the RGD sequence in vWF that mediates binding to GPIIb-IIIa. The latter antibody at 200 pg/mL completely inhibited shear-aggregation at 120 dyneslcm' and reduced it by about 90% at 180 dynes/ cm2 (data not shown). Figure 1A compares the inhibitory effect of rvWF445-733 and polymeric ATA on shear-induced, vWF-mediated platelet aggregation in normal citrated PRP at 180 dynes/cm2. rvWF"' 45-733 inhibited shear-aggregation in a dose-dependent manner, presumably by competing with large vWF multimers for binding to platelet GPIb. Shear-aggregation was totally absent in the presence of rvWF445-733 concentrations above 50 pg/mL (Fig  1 A) . Polymeric ATA also produced dose-dependent inhibition of shear-aggregation (Fig 1A) . The effect of different fluid shear stresses on the ability of 40 pg/mL rvWF445-733 or 80 pg/mL polymeric ATA to inhibit shear-aggregation in normal citrated PRP samples by these two different, "mirror-image" mechanisms is shown in Fig 1B. Figure 2 demonstrates that, in the viscometer using citrated PRP, the inhibitory effectiveness of a low concentration of rvWF445-733 (30 pg/mL) was counteracted by low concentrations of polymeric ATA (10 to 20 pg/mL). ATA and rvwF445-733 apparently interact with each other at these concentrations. At concentrations of ATA above 40 pg/mL, the inhibitory effect of ATA on shear-aggregation is neither compromised nor potentiated by the presence of 30 pg/mL rvwF445-733 Shear-aggregation was compared in normal PRP samples anticoagulated with sodium citrate, recombinant hirudin, unfractionated porcine heparin, or low molecular weight heparin (Fig 3) . Platelets in the PRP in each anticoagulant aggregated extensively (<20% remaining singlet platelets). These results indicate that neither the reduced calcium levels in the citrated PRP nor any interaction that may occur between plasma vWF multimers and unfractionated or low molecular weight heparin affects the extent of vWF-mediated platelet aggregation induced by shear stress (compared with hirudin-PRP). In the presence of rvWF445-733 (60 pg/mL), shear-aggregation in the PRP samples anticoagulated in citrate, hirudin, or low molecular weight heparin was almost completely reversed. In contrast, PRP anticoagulated with unfractionated porcine heparin and incubated with rvWF445"33 fully aggregated under these shear conditions. This was studied further by varying the amount of unfractionated porcine heparin added to nor-
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For (Fig 4) . The addition of unfractionated heparin alone in concentrations up to 5 U/mL had no effect on the extent of shear-aggregation, confirming the experiment in Fig 3. However, addition of 0.3 to 5 U/mL unfractionated heparin (concentrations that can be attained in vivo in humans) progressively counteracted the inhibitory effect of These results indicate that unfractionated with a range of concentrations of ATA on shear-induced platelet aggregation is not synergistic. The rvWFu6-733 was added to 10 to 100 pg/mL ATA and incubated for 5 minutes at room temperature.
Normal citrated PRP was added to this mixture and incubated for an additional 5 minutes before the application of fluid shear stress in a cone and plate viscometer. The shear stress was 180 dynes/ cm2 for 30 seconds at room temperature. The platelet counts in the PRP samples were 300,000 to 346,00O/pL.
heparin, but not low molecular weight heparin, apparently interacts with the heparin binding site of rvWF445-733 molecules and prevents it from competing with large vWF multimers for attachment to platelet GPIb. However, recently reported preliminary results suggest that this effect of heparin may not be so important when N W F~~~-~~~ is administered to intact animals.48 In contrast, unfractionated porcine heparin had no affect on the inhibition of shear-aggregation by 80 pg/mL polymeric ATA (data not shown).
Perfusion Experiments
Real-time analysis ofplatelet adhesion and subsequent aggregation onto collagen I-coated surfaces using normal blood. Table 1 shows the results of digital image analysis of platelet accumulation from citrate-anticoagulated whole blood of four normal donors onto type I collagen. The number of individual platelet thrombQ3.7 X lo4 pm', a measurement of the platelet adhesive events that initiate thrombus formation, increased during the initial 15 seconds of flow at 1,500 s-'. As individual platelet thrombi merge into larger clumps at 30 and 60 seconds of flow, the number of individual thrombi decreased concomitantly.
The total number of platelets in millions/cm2 that were deposited from normal blood onto type I collagen-coated slides using different anticoagulants (three experiments for each) were: 10.9 k 2.0 (citrate); 14.4 f 4.4 (porcine heparin, 4 U/mL); and 14.9 k 5.0 (low molecular weight heparin, 1 U/mL). In one similar type of experiment using 200 U/mL of recombinant hirudin as anticoagulant, a total of 8.3 million platelets/cm' were deposited on collagen I slides. The differences among the values are not statistically significant. Inhibition by rvWFu6-733 on fluid shear-induced, vWF-mediated platelet aggregation from PRP anticoagulated by 0.38% sodium citrate, 200 U/mL recombinant hirudin, I O U/mL unfractionated porcine heparin, or 1 U/mL low molecular weight heparin in a cone and plate viscometer. The shear stress was 180 dynes/cm2 for 30 seconds at room temperature. Platelet counts in the PRP samples were 246,000 to 360,00O/pL. < 1.5 U/dL) was anticoagulated with citrate and perfused at 1,500 s-' wall shear rate (60 dynes/cm2 wall shear stress) for 1 minute over a collagen type I-coated glass slide. On the first 10 mm downstream from the glass-collagen interface, a total of 2.4 X 106/cm2 platelets were deposited (almost entirely as single platelets or small clumps). This was in contrast to the adherence, and subsequent aggregation, of a total of 13.1 X 106/cm2 platelets if the vWD blood was incubated with 100 U/dL (100%) of purified large vWF multimers for 5 minutes before perfusion. The importance of vWF is shown in the three-dimensional reconstructions of the thrombi formed using severe vWD blood in the presence or absence of vWF (Fig 5) . The effect of the presence and absence of vWF is also demonstrated in Table 2 , which shows the video image processing data from the experiment in Fig 5. In severe vWD blood without added vWF, platelet adhesion (as expressed by the number of individual thrombi per unit surface area) at 15 seconds of flow and a wall shear rate of 1,500 s-l was only 3 1 % of that observed using severe vWD blood in the presence of 100 U/dL of purified vWF. The platelet thrombi formed from severe vWD blood were also considerably smaller in overall size distribution.
Effect of exogenous v WF on platelet adhesion and subsequent aggregation onto collagen I-coated surfaces using severe v W D blood. Whole blood from a severe vWD patient (vWF
Shear-rate dependence of platelet accumulation on collagen I: Contribution of v WF in plasma or released from platelets. Whole blood from a normal donor and a severe vWD patient with less than 1.5 U/dL plasma vWF was anticoagulated with porcine heparin and perfused at 100, 800, or 1,500 s-' wall shear rates for 2 minutes. Platelet deposition onto type I collagen from normal blood was shear rate-dependent, as shown by the progressive increase in platelet accumulation as the shear rate increased from 100 s-' to 1,500 s-' (Fig 6) . A promoting effect of vWF on platelet adherence to collagen I can be detected, even at 800 s-'. In contrast, increasing the shear rate had little effect on the number of platelets deposited onto collagen I from severe vWD blood. Reversal of the inhibitory effect of rvWFu6-7u (60 pg/mL) on shear stress-induced, vWF-mediated aggregation of platelets from citrated normal PRP in a cone and plate viscometer by the addition of unfractionated porcine heparin. The shear stress was 180 dynes/cm2 applied for 30 seconds at loom temperature. Platelet counts in the PRP samples were 230,000 to 360,OOO/pL. The rvWFu6-733 and unfractionated heparin were both added to the PRP and incubated for 5 minutes at room temperature before application of the shear stress.
After the washing and resuspension of severe vWD platelets in heparinized normal plasma, platelet accumulation on type I collagen at 1,500 s-' wall shear rate was 77% of the platelet deposition from normal blood under the same perfusion conditions. Platelet deposition was 44% if normal platelets were washed and resuspended in severe vWD plasma. The results of this single experiment suggest that both plasma vWF and vWF released from normal platelets can contribute to platelet adhesion and accumulation on collagen surfaces, and are compatible with a previous report by Fressinaud et al.49 Platelet vWF multimers are known to be released from the a-granules of platelets activated by abnormally elevated fluid shear stresses."
Eflect of anti-GPIb on platelet adhesion onto collagen Z. Figure 7 is a three-dimensional representation of platelet deposition onto type I collagen-coated surfaces using citrated normal whole blood that has been incubated in the presence or absence of 50 &mL of monoclonal anti-GPIb F(ab')*, and then perfused for 1 minute at 1,500 s-'. In the experiment 
C
C o n t r o l (anti-GPIh), 6 @ sec w of platelet adhesion flow using severe \ (measured as number of individual thrombi per unit surface area at 15 seconds) onto collagen I in the presence of antiGPIb F(ab'), (Table 3) . There was a reduction in total platelet deposition onto collagen I-coated surfaces in the presence of anti-GPIb F(ab')z by about 85% using citrated normal whole blood (n = 3; Table 4 ). In the presence of anti-GPIb F(ab'),, only a few single platelets or clumps with small numbers of platelets adhered to the collagen (Table 3 ). There was more platelet adhesion to collagen I under the same conditions of ' rWD blood with less than 1.5 U/dL plasma vWF and undetectable (or barely detectable) platelet vWF forms than in the presence of 50 pg/mL anti-GPIb F(ab')z. These findings suggest that only a small quantity of vWF insolubilized onto bovine collagen I is sufficient to initiate platelet adhesion via GPIb to this collagen type.
Eflects of antibodies against GPIIb-IIIa or the RGD sequence in v WF (GPIIb-IIIa binding region) on platelet adhesion and aggregation onto collagen I. Anti-GPIIb-IIIa or the antibody against the RGD sequence in vWF (both at pg/mL) were less inhibitory than the anti-GPIb F(ab), at 50 pg/mL on total platelet accumulation onto collagen I ( Table  4) . (These antibody concentrations caused complete inhibition of shear-induced, vWF-mediated aggregation in the viscometer.) Preincubation of blood with 200 pg/mL of MoAbs against GPIIb-IIIa or the RGD sequence in vWF suppressed platelet deposition onto collagen by about 67% and 39%, respectively (n = 3; Table 4 ). In the presence of anti-GPIIbIIIa, the number of platelet adhesive events (number of individual thrombi per unit surface area) was not decreased and thrombi consisting of one or two to five platelets were predominate ( Table 5 and Fig 8) . In the presence of anti-RGD in vWF there was a reduced rate of platelet aggregation, as indicated by the relatively stable number of individual thrombi over 60 seconds compared with controls (Table 5) and the three-dimensional images of platelet thrombus formation over time in bovine collagen type I-coated glass slides using heparinized blood from a normal donor and from a patient with severe vWD. The last two columns demonstrate the effect of either plasma vWF or vWF released from normal platelets on platelet accumulation onto colnormal whole blood was incubated for 5 minutes with polyl 4 AdmL) Or buffer and perfused at 1,500 S-' for 1 minute (Table 6 and Fig 10A) . There was ATA (28.5, 57, Or lasen. For these exDeriments: either severe vWD platelets with no concentration-deDendent inhibition of total Dlatelet accu--detectable platelet vWF were washed and resuspended in normal PPP, or normal platelets were washed and resuspended in severe vWD-PPP containing less than 1.5 U/dL vWF antigen. Normal mulation onto collagen, which was about 87% at 1 14 p g / m~ of polymeric ATA (Table 6 ). Inhibition was caused by ATA erythrocytes were added to produce final hematocrit values of 40%.
suppression of platelet adhesion to collagen I (Table and and platelets were 400,000/& Fig 11) .
For Citrated normal whole blood was also incubated for 5 minutes with 30, 60, or 200 pg/mL of rvWp45-733 and perfused at 1,500 s-' for 1 minute. A concentration-related inhibitory effect of rvWp5-733 on total platelet accumulation along collagen-coated surfaces is shown in Fig 1 OB and Table  6 . Similar results were obtained in one experiment with 30, 60, or 200 pg/mL of rvWF445-733 in normal blood anticoagulated with recombinant hirudin (not shown). Inhibition of total platelet inhibition was about 85% at 200 pg/mL of rvwF445-733 (Table 6 ). This inhibition was, as with polymeric ATA, to a considerable extent the result of interference with platelet adhesion to collagen I, and the subsequent formation of large platelet clumps (Table 8 and Fig 11) .
Citrated normal whole blood was incubated with either buffer or 60 pg/mL rvWF"45-733 and perfused for 1 minute at shear rates of 3,000, 1,500, 800, and 100 s-'. At each shear rate, the average number of platelets per cm2 deposited as a result of adherence and subsequent aggregation onto collagen I-coated surfaces was determined (Fig 12) . The inhibitory effectiveness of rvWp45-733 was greater at higher shear rates (n = 3 for each experimental condition). In one additional experiment using 120 pg/mL of rvWF445-733, qualitatively similar results were obtained (with an augmented extent of inhibition) at each shear rate (data not shown).
Incompatibility between unfractionated porcine heparin and rvWF445-733 (containing heparin binding sites) in perfusion experiments is shown in Fig 13. These results are similar to those obtained in the shear-aggregation studies. The inhibitory effect of 60 pg/mL rvWF445-733 on platelet adhesion to collagen type I from normal citrated whole blood at 1,500 s-' and 1-minute perfusion time was partially reversed as porcine hep- vWF multimers from normal plasma, the relatively large vWF multimeric forms purified from normal human cryoprecipitate, and vWF released from platelets apparently become insolubilized rapidly onto bovine fibrillar collagen type I under flowing conditions and are the predominate mediators of platelet-collagen adhesion at shear rates between 800 and 3,000 s-' in citrate, hirudin, and unfractionated porcine heparin. The latter does not detectably interfere with the adsorption of vWF multimers onto type I collagen, even though vWF monomers contain a binding site for unfractionated heparin. Other studies have shown that vWF deposited by endothelial cells in the extracellular matrix also supports platelet adhe~ion.~'-~* Anti-GPIb F(ab')* inhibited platelet adhesion to type I collagen at 1,500 s-' by 85% to 95%. Interfering with the function of either GPIb (using rvWF"45-733) or the GPIb binding site of vWF (using polymeric ATA) also suppressed platelet-collagen I adhesion under the same conditions of flow. Together with our experiments using severe vWD blood (~1 . 5 U/dL vWF antigen in plasma) in the presence and absence of vWF, these results establish with real-time observations and analysis that platelet adhesion from rapidly flowing blood onto collagen I is predominantly mediated by the interaction between collagen-associated insolubilized vWF multimers and platelet GPIb. Total platelet deposition onto collagen I/vWF at 1,500 s-' was inhibited by two thirds in the presence of anti-GPIIb- IIIa and the adherent platelets were mostly singlets or present in small clumps of 2 to 5. Using an antibody against the RGD sequence in vWF, total platelet deposition onto collagen I/vWF under these same perfusion conditions was reduced by about 40%. The inhibitory effect of the anti-RGD in vWF antibody was to slow the rate of formation of very large aggregates (>500 platelets/thrombus). These observations indicate that vWF multimers are involved in platelet-platelet cohesion (aggregation) in our perfusion model (as well as in the platelet adhesion to collagen I), even in the presence of the relatively high concentrations of fibrinogen and fibronectin in normal blood. Our finding that anti-GPIIb-IIIa was For personal use only. on October 3, 2017. by guest www.bloodjournal.org From In contrast to our results in the real-time perfusion system, the inhibitory effects of anti-GPIlb-IIIa and the antibody against the RGD sequence in vWF on shear-induced, vWFmediated aggregation in the cone and plate viscometer were as pronounced as the inhibitory effect ofanti-GPIb. Previous work has indicated that both vWF-GPIb and vWF-GPIIbIIIa interactions are required to induce direct platelet aggregation under the conditions of abnormally elevated fluid shear stresses in the vi~cometer.'~-'~ Our results lead to the conclusion that rvWF445-733 binds to platelet GPIb,19 competitively interferes with the attachment of large vWF multimers insolubilized onto collagen to this binding site, and inhibits platelet adhesion in a concentration-and shear ratedependent process. This interpretation is compatible with our finding that rvWF445-733 also interferes with GPlbdependent, shear-induced, vWF-mediated aggregation (which does not involve collagen).
Unfractionated porcine heparin in concentrations that can be attained in vivo interacts with rvWF445-733 and prevents it from competing with large vWF multimers for GPIb binding sites, and from exerting its inhibitory effects on shear-aggregation and platelet adhesion to collagen 1. These results suggest that the use of rvWF445-733 as an anti-thrombotic agent may potentially be compromised by the concurrent local or systemic administration of unfractionated heparin. However, it should be emphasized that we have performed only in vitro experiments. In vivo interactions between rvWF445-733 and unfractionated porcine heparin may not be similar for reasons that include, among others, differences in catabolism between the two compounds. Preliminary studies in pigs indicate that the concurrent use of rvWF445-733 and unfractionated heparin may be compatible in viv0.4~ It remains to be determined in humans if rvWF445-733 can be given along with unfractionated heparin and retain inhibitory effectiveness with respect to arterial thrombotic processes.
Polymeric ATA interacts with, and inhibits, GPIb binding sites on vWF multimers." Therefore, polymeric ATA and rvWF445-733 both block platelet GPIb-vWF interactions-but by "mirror image" mechanisms. Each is capable of inhibiting platelet adhesion from citrated or hirudin-treated whole blood onto collagen I/vWF in the perfusion system, as well as the For personal use only. on October 3, 2017. by guest www.bloodjournal.org From vWF AND PLATELET THROMBI UNDER FLOW 1275 direct aggregation of platelets from citrated or hirudin-anticoagulated PRP at an abnormally elevated level of fluid shear stress (1 80 dynes/cm2) in the viscometer. Inhibition of these events by more than 50% occur in vitro in both the perfusion and viscometer model systems at relatively low concentrations of rvWp45-733 or ATA (60 pg/mL).
In contrast to rvWF445-733, the inhibitory effect of polymeric ATA is not counteracted by unfractionated porcine heparin. However, negatively charged ATA molecules may attach to rvWp45-733 because the inhibitory effect of a relatively low concentration of N W F~~~-~~~ is reduced in the presence of low concentrations (10 to 20 pg/mL) of polymeric ATA. Because the shear and perfusion models may simulate conditions for the two mechanisms of platelet thrombus formation in vivo in humans, it will be prudent to consider in any therapeutic trials that the anti-arterial thrombotic potential of r v w p 4 5 -7 3 3 and polymeric ATA may be maximized if the two agents are administered separately.
